Hong Xia Wang

Sha Wang is the Founding Partner of Terra Magnum Capital Partners.
Ms. Wang is on the Firm's Investment Committee and leads Terra Magnum Capital's investments in buyout, fund investments and direct co-investments.
In addition, she oversees investor relations, asset allocation and investment strategy and process.
Ms. Wang has over 15 years' experience investing in both the US and Asia's private equity markets, with investments including Alibaba's IPO (NYSE:BABA), Wuxi Pharma (HKG:2269 & SHA:603259), Viela Bio (NASDAQ:VIE), Erasca, Immunocore, Flame Biosciences, Berry Genomics (SZ:000710), CStone Pharma (HKG:2616), Hansoh Pharma (HKG:3692) and Tigermed (HKG:3347); In addition, Ms. Wang's fund investments included Boyu Capital, KKR China, Illumina Ventures, Sherpa Healthcare Partners and Creacion Ventures, etc Previously, Ms. Wang was a Principal at Cybernaut (China) Investment, a China and US-focused private equity and venture capital fund with assets under management exceeding $500 million.
Prior to 2008, Ms. Wang was a Vice President and Director of China investments at Opus8, a private investment firm in Washington DC, where she was primarily responsible for the China fund and direct investments in the service sector.
Prior to joining Opus8, Ms. Wang was with ING Asia Investment Management in Hong Kong, focusing on QFII/QDII issues at China Merchant Fund, a joint venture between ING and China Merchant Bank.
Ms. Wang received her executive MBA from the People's Bank of China School of Finance at Tsinghua University (Top EMBA program in Asia that had been an intellectual home to some of Asia's finest financial minds), holds a Ph.D.
in Electrical Engineering from the University of Maryland, College Park and currently serves as the program mentor at Cornell-Tsinghua MBA/FMBA.
Ms. Wang is fluent in Mandarin Chinese and English.